Table 4 The NMA presents the impact of each intervention for overall survival
Placebo | 0.97 (0.83,1.12) | 1.03 (0.91,1.16) | 0.96 (0.72,1.30) | 1.05 (0.90,1.23) | 1.33 (0.80,2.21) | 1.00 (0.75,1.35) |
0.97 (0.83,1.12) | sunitinib | NA | NA | NA | NA | NA |
1.03 (0.91,1.16) | 1.06 (0.87,1.29) | sorafenib | NA | NA | NA | NA |
0.96 (0.72,1.30) | 1.00 (0.72,1.39) | 0.94 (0.68,1.30) | IL2 + IFN + 5FU | NA | NA | NA |
1.05 (0.90,1.23) | 1.09 (0.88,1.35) | 1.03 (0.84,1.25) | 1.09 (0.78,1.53) | pazopanib | NA | NA |
1.33 (0.80,2.21) | 1.37 (0.81,2.33) | 1.30 (0.77,2.19) | 1.38 (0.76,2.49) | 1.26 (0.74,2.15) | pembrolizumab | NA |
1.00 (0.75,1.35) | 1.04 (0.75,1.44) | 0.98 (0.71,1.35) | 1.04 (0.69,1.58) | 0.95 (0.68,1.33) | 0.76 (0.42,1.36) | girentuximab |